Avicanna | A Leader in Biopharmaceutical Advancement

Driving Biopharmaceutical Advancement of Evidence-Based, Cannabinoid Products

Who We Are

Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments

We are an international biopharmaceutical company focused on the research, development, and commercialization of cannabis-derived products, particularly in the field of medical cannabis. Founded in Canada, we emphasize the development of advanced formulations and delivery systems for cannabinoids, aiming to meet various therapeutic needs. We work on developing products for different health conditions, and our work includes a focus on science, innovation, and clinical development.

Corporate Overview

Corporate Highlights

4 commercial stage business pillars

30+ Commercialized Proprietary products

314% year-over-year growth in revenue

Completed transactions in 20+ countries

Scientific Platform

Established industry leading R&D and scientific infrastructure

JLABS @Johnson and Johnson incubated – at MaRS

Proprietary and indication specific pharmaceutical pipeline

Research and clinical partnerships with leading academic and clinical institutions

Medical affairs and clinical development platform

Intellectual Property and Brands Owned by Avicanna

Medical Cannabis Products and RHO Phyto – Commercial

Medical Cannabis Pharmacy Platform – Launched August

Pharmaceutical Products – In development and registration stages

Active Pharmaceutical Ingredients – Aureus Santa Marta

Four Commercial Stage Business Pillars

Avicanna’s scientific platform has resulted in 30+ proprietary formulations and commercial products

Including medical cannabis, medical cannabis care, Pharmaceutical products and active pharmaceutical ingredients

Medical Cannabis Care Platform

Medical Cannabis Products

Pharmaceutical Products

Active Pharmaceutical Ingredients

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products

R&D headquarters in Toronto, Canada with drug development pipeline including sustained release tablets, transdermal patches and nano-particle formulations.

30+

Proprietary Commercial Products

10+

Scientists

Canadian Government Research Grants Awarded Since 2020

Health Canada Cannabis
Research Licenses to Avicanna
or Institutional Collaborators

Several issued and pending patents

World-class Institutional Collaborations

R&D and Clinical Partnerships Over the Past 6 Years

World-Class Institutional Collaborations

20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017

Majority of the research has been conducted in Canada through 4 Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators.